Abstract
Background: Benzo[h]chromenes attracted great attention because of their widespread biological activities, including anti-proliferate activity, and the discovery of novel effective anti-cancer agents is imperative.
Objective: The main objective was to synthesize new benzo[h]chromene derivatives and some reported derivatives, and then test all of them for their anti-cancer activities.
Methods: The structures of the newly synthesized derivatives were confirmed by elemental and spectral analysis (IR, Mass, 1H-NMR and 13C-NMR). 35 compounds were selected by the National Cancer Institute (NCI) for single-dose testing against 60 cell lines and 3 active compounds were selected for 5-doses testing. Also, these 3 compounds were tested as EGFR-inhibitors; using sorafenib as standard, and as Tubulin polymerization inhibitors using colchicines as a standard drug. Moreover, molecular docking study for the most active derivative on these 2 enzymes was also carried out.
Results: Compounds 1a, 1c and 2b have the highest activities among all 35 tested compounds especially compound 1c.
Conclusion: compound 1c has promising anti-cancer activities compared to the used standards and may need further modification and investigations.
Keywords: Benzo[h]chromene, synthesis, anti-cancer activity, 5-doses testing, EGFR-inhibitors, tubulin polymerization inhibitors.
Graphical Abstract
[http://dx.doi.org/10.1158/1055-9965.EPI-15-0578] [PMID: 26667886]
[http://dx.doi.org/10.1016/j.jmgm.2018.02.013] [PMID: 29609141]
[http://dx.doi.org/10.1016/j.bmcl.2015.03.034] [PMID: 25838145]
[http://dx.doi.org/10.1016/j.cclet.2015.09.020]
[http://dx.doi.org/10.1111/cbdd.12653] [PMID: 26301627]
[http://dx.doi.org/10.1002/ejoc.201301792]
[PMID: 28828001]
[http://dx.doi.org/10.1111/j.1747-0285.2010.00959.x] [PMID: 20337782]
[http://dx.doi.org/10.1016/j.phymed.2006.09.002] [PMID: 17140782]
[http://dx.doi.org/10.1002/ardp.201100335] [PMID: 22189501]
[http://dx.doi.org/10.1021/jm900146e] [PMID: 19366247]
[PMID: 15542775]
[http://dx.doi.org/10.1021/jm060353u] [PMID: 16722623]
[http://dx.doi.org/10.1016/j.lfs.2005.06.017] [PMID: 16153663]
[http://dx.doi.org/10.1590/S0103-50532010000600010]
[http://dx.doi.org/10.1016/j.bmcl.2011.09.053] [PMID: 21983443]
[http://dx.doi.org/10.2174/1871520610909040437] [PMID: 19442043]
[http://dx.doi.org/10.1016/j.bmcl.2008.09.011] [PMID: 18805007]
[http://dx.doi.org/10.1021/jm7010657] [PMID: 18197614]
[http://dx.doi.org/10.1021/mp7000846] [PMID: 17874842]
[http://dx.doi.org/10.4155/fmc.13.126] [PMID: 24047270]
[http://dx.doi.org/10.1073/pnas.97.13.7124] [PMID: 10860979]
[http://dx.doi.org/10.1021/jm060968r] [PMID: 17181155]
[http://dx.doi.org/10.1016/j.bmcl.2012.04.074] [PMID: 22608389]
[http://dx.doi.org/10.1074/jbc.272.12.7681] [PMID: 9065425]
[http://dx.doi.org/10.1124/mol.52.3.437] [PMID: 9281606]
[PMID: 23226110]
[PMID: 9562601]
[http://dx.doi.org/10.18632/oncotarget.17549] [PMID: 28978013]
[http://dx.doi.org/10.1016/j.ejmech.2018.03.001] [PMID: 29549841]
[http://dx.doi.org/10.2174/1871520617666170102152928] [PMID: 28042776]
[http://dx.doi.org/10.1007/s00044-010-9399-x]
[http://dx.doi.org/10.1016/j.ejmech.2010.08.014] [PMID: 20805011]
[http://dx.doi.org/10.1002/jhet.2630]
[http://dx.doi.org/10.1039/c0gc00387e]
[http://dx.doi.org/10.1021/jm00120a002] [PMID: 2848124]
[http://dx.doi.org/10.1038/nrc1951] [PMID: 16990858]
[http://dx.doi.org/10.1002/ddr.430340203]
[http://dx.doi.org/10.1039/C5MD00293A]
[PMID: 3972806]
[http://dx.doi.org/10.1038/359533a0] [PMID: 1406970]
[http://dx.doi.org/10.1038/347780a0] [PMID: 2146510]
[PMID: 4830832]
[http://dx.doi.org/10.1126/science.1075762] [PMID: 12471243]
[http://dx.doi.org/10.1007/s00018-008-8539-7] [PMID: 19011754]
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[http://dx.doi.org/10.2478/v10007-009-0016-9] [PMID: 19564140]
[http://dx.doi.org/10.3390/molecules15031882] [PMID: 20336018]
[http://dx.doi.org/10.1002/ardp.201400387]